Abstract:Abstract Activation of the tumor suppressor p53, through inhibition of the MDM2 protein, has been pursued as a cancer therapeutic strategy and has produced many distinct inhibitors that are in clinical trials. A limitation arising from inhibiting the MDM2-p53 interaction is the upregulation of MDM2, itself a target gene of p53, and this attenuates the activation of p53 and efficacy of the inhibitors. To circumvent this limitation, we previously reported the first PROTAC based MDM2 degraders. These induced and sustained robust degradation of MDM2, achieved stronger p53 activation, and more potent anticancer activity than MDM2 inhibitors thus representing a new therapeutic strategy for targeting MDM2. Currently, all the PROTAC based MDM2 degraders are all dosed intravenously. Here we describe our design, synthesis, and optimizations that led to the discovery of the first orally bioavailable PROTAC based MDM2 degrader and our investigation of its therapeutic potential and mechanism of action. Consistent with its design to effectively degrade MDM2, our PROTAC effectively induces rapid degradation of MDM2 resulting in accumulation of wild-type p53 protein and activates p53 transcriptional activity in leukemia cells without accumulation of MDM2 protein. Consequently, it potently inhibits cell growth and induces apoptosis at low nano-molar concentrations in ALL and AML cell lines >10-100 times more potent than MDM2 inhibitors; and, after 50 mg/kg oral dose, 5 days/week for 3 weeks, it increased the median survival by 26 days of mice with disseminated RS4;11 cancer. Citation Format: Angelo Aguilar, Jiuling Yang, Yangbing Li, Donna McEachern, Shaomeng Wang. Orally bioavailable PROTAC based MDM2 degrader [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4515.

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer

Promising Proteolysis-Targeting Chimera for Mutant p53-R175H

An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer

Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53

Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction

PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: an Updated Perspective.

Abstract 4515: Orally bioavailable PROTAC based MDM2 degrader

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

Targeting P53 for Novel Anticancer Therapy.

Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells

Discovery of a potent PARP1 PROTAC as a chemosensitizer for the treatment of colorectal cancer

DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice

PROTACs: A novel strategy for cancer therapy

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation

p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation

Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression